DNB // Back Bay takes the pulse of the life science market
In the report "Vital Signs: A Pulse Check on the Healthcare Market" DNB // Back Bay's investment banking division takes a close look at the current macroeconomic situation in the US markets, with a particular focus on the latest policy and regulatory updates. It examines the current administration's comprehensive reform of US healthcare policy and its impact on the life sciences ecosystem. It also examines the level of activity in the healthcare market and how these factors are affecting business activity and deals in both the US and Europe.
Notes
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
OncoZenge enters into convertible loan with Linc
NEWSLETTER
NEWS
AlzeCure Pharma: “We have good momentum”
Modus Therapeutics CEO comments on latest milestone
The new era of weight loss: Does GLP-1 live up to expectations?
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
